Singapore ADHD Therapeutics Market Report 2022 to 2030

Singapore ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

Singapore's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $35 Mn in 2022 to $66 Mn in 2030 with a CAGR of 8.1% for the year 2022-30. The increasing demand for ADHD therapeutics and supportive government initiatives taken by Singapore are the major factors driving the growth of the market. The Singapore ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the key players in the market are Ziwell Medical, Moleac, and Alcobra.

ID: IN10SGPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Parul Choudhary

Buy Now

Singapore Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Singapore Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $35 Mn in 2022 and is projected to reach $66 Mn in 2030, exhibiting a CAGR of 8.1% during the forecast period. Total spending in Singapore across all ministries is anticipated to grow from 2022 to $77.76 Bn in FY 2023. $12.59 Bn is anticipated to be spent overall on health. The Singapore General Hospital's Emergency Medicine Building and Elective Centre, as well as IT infrastructure for new healthcare facilities and other significant IT initiatives, will all receive funding totaling $1.02 Bn from the Health Ministry.

The neuro-developmental condition of attention deficit hyperactivity disorder (ADHD) is characterized by early-onset hyperactive-impulsive and/or inattentive symptoms that are persistent, pervasive, and debilitating. The pooled frequency across the globe was about 5.29%. Although there hasn't been an epidemiological study on the prevalence of this condition among children in Singapore, a local study found that 4.9% of Singaporean primary school students had externalizing issues. Doctors generally prefer to wait until the child is 6 or 7 years old, when the child has more control over his or her behavior, even though ADHD can be diagnosed as early as the age of 5. A diagnosis of ADHD can only be made if the signs start before the age of 12 and can be seen in more than two contexts (such as school and home).

Even though ADHD cannot be cured, adult ADHD medication or counseling can help reduce the symptoms. ADHD symptoms are usually treated by doctors in Singapore using stimulant medications like methylphenidate. These aid in impulsivity, focus, and attention. However, drugs that are used to treat conditions like depression and others can also be used to address ADHD symptoms. For many people, the best course of treatment entails a combination of medication and counseling. A recognized treatment for ADHD, cognitive behavioral therapy (CBT) helps to lessen problematic behaviors and routines while enhancing coping and problem-solving abilities. These days, an 8-hour version of Ritalin is more frequently used. Medikinet and Ritalin SR are the two brands available in Singapore. This guarantees that a single dosage taken in the morning will at least last an entire school day.

singapore attention deficit therapeutics market

Market Dynamics

Market Growth Drivers

The number of individuals in Singapore who have been given an ADHD diagnosis has increased recently, which has increased the demand for ADHD medications and other treatments. People with ADHD now have greater access to care and treatment due to new technologies like digital health platforms and telemedicine. The Singaporean government has supported initiatives to enhance ADHD detection and care. For instance, the Ministry of Health has started programs to raise awareness of ADHD among the general population and medical professionals hence driving the growth of Singapore ADHD therapeutics market.

Market Restraints

Although there has been an increase in awareness of ADHD in Singapore, there is still a sizable knowledge gap among the general population, medical professionals, and instructors. Misdiagnosis and inadequate treatment of ADHD may impede the expansion of the Singapore ADHD therapeutics market. The COVID-19 pandemic-related global economic downturn may influence Singapore's ADHD market development because patients and healthcare providers may experience financial hardships.

Competitive Landscape

Key Players

CCM Pharmaceuticals (SGP)
Capsule Pharma (SGP)
Eshcol Pharmaceutical (SGP)
Ziwell Medical (SGP)
Moleac (SGP)
Alcobra
Amarantus Bioscience
Curemark
Eli Lilly
Intellipharmaceutics
Janssen Global
Mallinckrodt

Healthcare Policies and Regulatory Landscape

The Health Sciences Authority (HSA) of Singapore is tasked with overseeing the development of national drug policies and ensuring that medicines, novel therapeutics, medical devices, and other health products adhere to the necessary safety, quality, and efficacy standards. To grant approvals that permit products to be sold in Singapore, the HSA evaluates product registration applications, examines clinical drug trials, and audits good manufacturing and distribution practices. The HSA monitors medical products for regulatory compliance, enacts sanctions against unlawful behavior, and reacts to adverse drug events during the post-market phase. The HSA makes a distinction between biological and chemical therapeutic goods. Additionally, there are two types of applications: generic drug applications (GDA) and novel drug applications (NDAs). A GDA is used when a chemical product has the same active component makeup, dosage form, and clinical indication as a similar but not identically registered product. Biosimilar products cannot be filed through a GDA; instead, they require an NDA.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.